Related Experiment Videos
Adjuvant regional chemotherapy in advanced pancreatic cancer: results of a prospective study
H G Beger1, K H Link, F Gansauge
1Department of General Surgery, University of Ulm, Germany.
Background/Aims:
In order to improve the dismal prognosis of patients suffering from advanced pancreatic cancer we treated 20 patients with adjuvant regional chemotherapy following resection of the tumor.
Methodology:
All tumors were classified UICC stage III (TxN1M0). Regional chemotherapy consisted of Mitoxantrone 10 mg/m2 day 1, Folinic Acid 170 mg/m2 and 5-FU 600 mg/m2 days 2-4, and cis-Platinum 60 mg/m2 day 5 for up to 6 cycles. In a total of 101 cycles toxicities WHO III occurred in 6%, WHO IV in 0%.
Results:
The median survival times, compared to institutional historical controls (treated vs. controls) were 18.5 vs. 9.3 months (p < 0.0006). Hepatic disease progression seemed to be suppressed.
Conclusion:
In conclusion regional chemotherapy seems to be effective for adjuvant treatment in resected pancreatic cancer.